Literature DB >> 27215754

[Psoriasis in special localizations].

A Schmieder1, W K Peitsch2.   

Abstract

A large proportion of patients with plaque psoriasis suffer from psoriatic lesions of the scalp, nails, and intertrigines. These locations can also be soley or predominantly affected. Scalp psoriasis, nail psoriasis, and inverse psoriasis are often perceived as particularly stigmatizing. Involvement of these parts of the body is associated with an increased risk of psoriatic arthritis. Location-specific features must be considered when choosing treatment. Evidence for topical therapy of scalp psoriasis with steroids and combinations of steroids and vitamin D analogues is high. These agents are regarded as safe and effective treatments of first choice. Efficacy of TNF antagonists and apremilast is well documented for refractory scalp psoriasis. Nail psoriasis often responds insufficiently to topical therapy. Several effective systemic medications including methotrexate and TNF antagonists are available for treatment of severe forms. Controlled trials for treatment of inverse psoriasis are scarce. Topical steroids, vitamin D analogues, dithranol, and off-label calcineurin inhibitors are used in clinical practice. This review provides a survey on the clinical presentation and current evidence for treatment of psoriasis in challenging locations.

Entities:  

Keywords:  Biologicals; Intertrigo; Nail; Scalp; Topical steroids

Mesh:

Substances:

Year:  2016        PMID: 27215754     DOI: 10.1007/s00105-016-3806-2

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  36 in total

1.  Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream.

Authors:  D Rigopoulos; D Ioannides; N Prastitis; A Katsambas
Journal:  Acta Derm Venereol       Date:  2002       Impact factor: 4.437

2.  Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study.

Authors:  Dimitrios Rigopoulos; Stamatis Gregoriou; Andreas Katsambas
Journal:  Acta Derm Venereol       Date:  2007       Impact factor: 4.437

3.  Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles).

Authors:  M Sánchez-Regaña; M J Aldunce Soto; I Belinchón Romero; M Ribera Pibernat; R F Lafuente-Urrez; J M Carrascosa Carrillo; C Ferrándiz Foraster; L Puig Sanz; E Daudén Tello; D Vidal Sarró; R Ruiz-Villaverde; E Fonseca Capdevila; M C Rodríguez Cerdeira; M M Alsina Gibert; E Herrera Acosta; S E Marrón Moya
Journal:  Actas Dermosifiliogr       Date:  2014-05-19

4.  Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study.

Authors:  M Gümüşel; M Özdemir; I Mevlitoğlu; S Bodur
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-12-01       Impact factor: 6.166

5.  A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.

Authors:  J P Ortonne; C Paul; E Berardesca; V Marino; G Gallo; Y Brault; J M Germain
Journal:  Br J Dermatol       Date:  2013-05       Impact factor: 9.302

6.  Tacrolimus ointment is effective for facial and intertriginous psoriasis.

Authors:  Mark Lebwohl; Amy Krupnick Freeman; M Shane Chapman; Steven R Feldman; Jennifer E Hartle; Alice Henning
Journal:  J Am Acad Dermatol       Date:  2004-11       Impact factor: 11.527

7.  Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study.

Authors:  C De Simone; A Maiorino; F Tassone; M D'Agostino; G Caldarola
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-07-13       Impact factor: 6.166

8.  Scalp psoriasis: European consensus on grading and treatment algorithm.

Authors:  Jp Ortonne; S Chimenti; T Luger; L Puig; F Reid; R M Trüeb
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-07-15       Impact factor: 6.166

9.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

Authors:  Arthur Kavanaugh; Iain McInnes; Philip Mease; Gerald G Krueger; Dafna Gladman; Juan Gomez-Reino; Kim Papp; Julie Zrubek; Surekha Mudivarthy; Michael Mack; Sudha Visvanathan; Anna Beutler
Journal:  Arthritis Rheum       Date:  2009-04

10.  Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.

Authors:  Phoebe Rich; Christopher E M Griffiths; Kristian Reich; Frank O Nestle; Richard K Scher; Shu Li; Stephen Xu; Ming-Chun Hsu; Cynthia Guzzo
Journal:  J Am Acad Dermatol       Date:  2007-12-20       Impact factor: 11.527

View more
  2 in total

1.  [Use of salicylic acid oils on the scalp].

Authors:  S Melhorn
Journal:  Hautarzt       Date:  2017-03       Impact factor: 0.751

2.  [Psoriasis].

Authors:  R Sabat; M P Schön; K Schäkel
Journal:  Hautarzt       Date:  2016-06       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.